Carecloud Inc Stock Price, News & Analysis

CareCloud (Nasdaq: CCLD), a healthcare technology and generative AI solutions provider for medical practices and health systems, has scheduled its fourth quarter and full year 2024 financial results announcement for March 13, 2025, before market opening. The company will host a conference call for investors at 8:30 a.m. Eastern Time.

Investors can access the live webcast and presentation slides at ir.carecloud.com/events, or join via audio-only by dialing 201-389-0920. A replay will be available approximately three hours after the call's conclusion at the same link, with an audio-only option available at 412-317-6671 (access code: 13751992).

CareCloud (Nasdaq: CCLD) has announced the transfer of funds for January 2025 dividend payments on its Series A and Series B Preferred Stock. Series A stockholders will receive 22.917 cents per share, while Series B stockholders will receive 18.229 cents per share, based on the January 31, 2025 record date.

The payments are expected to be reflected in shareholders' brokerage accounts between February 18 and February 20, 2025. Both Series A and Series B Preferred Stock dividends are cumulative and payable monthly in arrears on the 15th of each month or the next business day. Due to President's Day on February 17th, payments will begin processing on February 18th.

CareCloud (Nasdaq: CCLD) has launched a new advanced referral module for its AI-enabled EHR system, achieving up to 70% time savings in referral management. The module streamlines the referral process through automation and location-based guidance, receiving an exceptional rating from 92% of surveyed users.

Key features include real-time referral completion during patient visits, location-based specialist recommendations, secure patient notifications via text messages, seamless appointment booking, and easy access to referral documentation through Personal Health Record (PHR). The system enables providers to complete referrals during patient visits and allows patients to receive specialist recommendations with integrated maps, book appointments directly, and access their referral forms securely.

CareCloud (Nasdaq: CCLD) has successfully completed its SOC 2 Type 2 examination for the second consecutive year, receiving a clean report with no exceptions. The examination, conducted by an independent CPA firm, covered security, availability, processing integrity, and confidentiality of Healthcare IT systems.

This achievement places CareCloud among an exclusive group representing less than 10% of all EHR vendors with such attestation. The certification validates the company's robust security infrastructure and demonstrates its capability to protect sensitive healthcare data, particularly important for larger enterprises such as health systems and hospital networks.

The attestation positions CareCloud for expanded growth into larger client bases, including health systems, multi-specialty group practices, and enterprise-level healthcare organizations that require stringent security and compliance frameworks for their operations.

CareCloud (Nasdaq: CCLD), a healthcare technology and generative AI solutions provider, has announced its participation in The Microcap Conference 2025, scheduled for January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.

The company's management team will deliver a corporate presentation highlighting recent developments and strategic initiatives. They will also engage in one-on-one meetings with institutional and individual investors. Co-CEO Stephen Snyder emphasized several key milestones, including the planned resumption of Preferred Stock dividends in February 2025, shareholder approval for increasing authorized common shares, and strong profitability growth during 2024.

CareCloud (CCLD) held a Special Meeting where shareholders voted to approve an amendment to increase the company's authorized common stock shares from 35 million to 85 million. The meeting saw a record-breaking turnout with 10.8 million shareholders participating, representing 85% of the votes cast in favor of the proposal. Stephen Snyder, Co-Chief Executive Officer, expressed gratitude for the overwhelming shareholder support. Detailed voting results will be filed with the SEC via Form 8-K.

CareCloud (NASDAQ: CCLD) announced that shareholders have tentatively approved a proposal to increase authorized common shares from 35 million to 85 million. The company received approximately 10.4 million votes by proxy in favor of the increase, representing over 80% of total votes submitted - one of the highest levels of positive votes in the company's history. The final vote count will be announced after the Common Stock Shareholder Special Meeting on January 27, 2025.

CareCloud (CCLD) has announced the early resumption of dividend payments for its Series A and Series B Preferred Stock, citing strong financial performance and accelerated free cash flow. The Board declared dividends for January and February 2025, with payments set at $0.18229 per share for both series, payable on February 18 and March 17, 2025.

For Series A Preferred Stock, additional catch-up payments of $0.04688 per share will be included to account for previous months when dividends accumulated at 11%. The Board plans to continue the higher effective rate of 11% for approximately 8 more months before reducing it to 8.75% annually. The current redemption value for Series A shares would be $28.17, while Series B shares would be $28.43 if redeemed today.

CareCloud announced that approximately 94% of the shares represented by proxies submitted to-date for the common stock special meeting scheduled for January 27, 2025 have voted FOR the Board-supported proposal to increase the number of authorized shares. This Proposal aims to provide the Company with greater strategic flexibility. The additional shares will enable CareCloud to pursue future acquisitions, support organic expansion, and facilitate the potential conversion of the Company’s outstanding Series A Preferred Stock into common stock. The increase also supports other corporate objectives to position the Company for long-term growth.

Stephen Snyder, Co-CEO of CareCloud, expressed enthusiasm for the overwhelming shareholder support, highlighting the company's standout performance in 2024 with an in-year appreciation of over 140%. Approval of the Proposal is seen as vital to enhancing shareholder value, providing tools to drive sustained revenue and profitability growth in the coming years. Shareholders are encouraged to submit their proxies before the January 23, 2025, deadline.

This press release summarizes information from the Definitive Proxy Statement and related filings with the U.S. Securities and Exchange Commission (SEC). Shareholders are encouraged to review these documents in their entirety, available on the SEC’s website and at CareCloud’s investor relations page.